Vinay Prasad is returning to his role at the FDA as the leader of the Center for Biologics Evaluation and Research at the request of the agency. His departure in July was marked by a conservative backlash regarding his safety handling of therapies from Sarepta Therapeutics, which included demands for additional studies on Covid vaccines. His approach was often seen as confrontational, leading to criticism about hindering scientific progress. The return has implications for ongoing regulatory discussions and biotech markets, as shares rose following his ousting.
Prasad will resume leadership of the Center for Biologics Evaluation and Research, and it remains uncertain whether he will retake two additional roles at the FDA.
Prasad's tenure as a regulatory leader was brief yet contentious, involving demands for more studies on Covid vaccines and confrontations that affected perceptions of scientific advancement.
Collection
[
|
...
]